Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BioAtla (BCAB) Assets (2020 - 2025)

BioAtla (BCAB) has disclosed Assets for 6 consecutive years, with $13.8 million as the latest value for Q4 2025.

  • For Q4 2025, Assets fell 73.62% year-over-year to $13.8 million; the TTM value through Dec 2025 reached $13.8 million, down 73.62%, while the annual FY2025 figure was $13.8 million, 73.62% down from the prior year.
  • Assets hit $13.8 million in Q4 2025 for BioAtla, down from $15.9 million in the prior quarter.
  • Across five years, Assets topped out at $277.6 million in Q3 2021 and bottomed at $13.8 million in Q4 2025.
  • Average Assets over 5 years is $143.0 million, with a median of $165.5 million recorded in 2023.
  • Year-over-year, Assets rose 3.87% in 2021 and then tumbled 74.44% in 2025.
  • BioAtla's Assets stood at $254.4 million in 2021, then decreased by 11.27% to $225.7 million in 2022, then tumbled by 46.99% to $119.7 million in 2023, then tumbled by 56.19% to $52.4 million in 2024, then plummeted by 73.62% to $13.8 million in 2025.
  • According to Business Quant data, Assets over the past three periods came in at $13.8 million, $15.9 million, and $27.1 million for Q4 2025, Q3 2025, and Q2 2025 respectively.